Stock CRIS CURIS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Curis, Inc.

Equities

CRIS

US2312693094

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 07:15:50 29/04/2024 pm IST 		5-day change 1st Jan Change
14.4 USD -0.48% Intraday chart for Curis, Inc. -3.03% +12.94%
09/02 HC Wainwright Adjusts Price Target on Curis to $26 From $51, Maintains Buy Rating MT
08/02 Curis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.

Number of employees: 49

Sales per Business

USD in Million2022Weight2023Weight Delta
Discovery and Development of Innovative Drug
100.0 %
10 100.0 % 10 100.0 % -1.37%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
10 100.0 % 10 100.0 % -1.37%

Managers

Managers TitleAgeSince
James Dentzer CEO
 Chief Executive Officer 57 29/16/29
Diantha Duvall DFI
 Director of Finance/CFO 52 26/22/26
Kimberly Steinmann CTO
 Chief Tech/Sci/R&D Officer - 03/22/03
Reinhard von Roemeling CTO
 Chief Tech/Sci/R&D Officer - 13/19/13
Robert E. Martell CTO
 Chief Tech/Sci/R&D Officer 61 01/11/01
Mark W. Noel CTO
 Chief Tech/Sci/R&D Officer 65 01/01/01
Rachel Blasbalg HRO
 Human Resources Officer - 01/04/01
Dora Ferrari PRN
 Corporate Officer/Principal - 03/21/03
Nancy Soohoo LAW
 General Counsel - 01/03/01
Jonathan Zung PRN
 Corporate Officer/Principal 59 01/23/01

Members of the board

Members of the board TitleAgeSince
Kenneth I. Kaitin BRD
 Director/Board Member 71 01/03/01
Martyn D. Greenacre CHM
 Chairman 82 14/00/14
James Dentzer CEO
 Chief Executive Officer 57 29/16/29
Marc Rubin BRD
 Director/Board Member 69 03/10/03
Robert E. Martell CTO
 Chief Tech/Sci/R&D Officer 61 01/11/01
Anne Borgman BRD
 Director/Board Member 56 -
John Hohneker BRD
 Director/Board Member 64 02/21/02

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 5,894,085 5,883,204 ( 99.82 %) 0 99.82 %

Shareholders

NameEquities%Valuation
Maverick Capital Ltd.
9.879 %
582,273 9.879 % 6 M $
M28 Capital Management LP
7.159 %
421,951 7.159 % 5 M $
Kingdon Capital Management LLC
5.866 %
345,730 5.866 % 4 M $
Kingdon Capital Management LLC
4.821 %
284,150 4.821 % 3 M $
Vanguard Global Advisers LLC
3.537 %
208,476 3.537 % 2 M $
Artal Group SA
1.781 %
105,000 1.781 % 1 M $
Citigroup Global Markets, Inc. (Investment Management)
1.559 %
91,872 1.559 % 998 649 $
Renaissance Technologies LLC
1.530 %
90,163 1.530 % 980 072 $
Geode Capital Management LLC
1.063 %
62,682 1.063 % 681 353 $
BlackRock Institutional Trust Co. NA
0.9074 %
53,484 0.9074 % 581 371 $

Company contact information

Curis, Inc.

Building C 128 Spring Street

02421, Lexington

+617 503 6500

http://www.curis.com
address Curis, Inc.(CRIS)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Curis, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
14.47 USD
Average target price
77.4 USD
Spread / Average Target
+434.90%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CURIS, INC. Stock Curis, Inc.
+12.94% 85.29M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+2.21% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+47.75% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+11.30% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.89% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.73% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.79% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.99% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+8.07% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CRIS Stock
  4. Company Curis, Inc.